...Teva Pharmaceuticals LTD Clinton Stucker American Military University Abstract In this paper we will discuss the competitive advantage of Teva Pharmaceuticals as well as Teva’s resources to continue to grow and remain dominant within the pharmaceutical industry. As industries evolve it is important for companies to evaluate their strengths and weaknesses in order to maximize their potential to succeed. In this paper we will evaluate Teva’s greatest strengths and resources that will enable the company to continue to grow and compete within the generic drug industry. This paper will be a guideline for how Teva should move it company forward in the future. Introduction Teva pharmaceuticals is known for its operational efficiency within the generic pharmaceutics industry. Information gathered from TevaPharm.com provides a clear picture of how the company is so successful within the pharmaceutical industry; Teva pharmaceuticals operates globally within sixty countries and consists of fifty four pharmaceutical production plants. The Teva company is a global industry that maintains a completive advantage as “During 2012, Teva's plants manufactured approximately 73 billion tablets and capsules and over 720 million sterile units (Tevapharm.com)”. Teva’s Competitive Advantage The Teva pharmaceutical company enjoys a serious competitive advantage within the generic pharmaceutical industry. Their biggest advantages include their operational expertise as well as their immense...
Words: 885 - Pages: 4
...Teva Pharmaceutical Industries, Ltd 1) External Environment: The Pharmaceutical Industry is dependent on political and legal conditions of general environment. In pharmaceutical industry we have two kind of medications which are generic or innovative. Innovative pharmaceutical industry success depends on the patent protection in the industry. For example, in United States innovative industry can have 10 to 12 years of patent protection life from the time that product is for sale in the market. Success of the generic pharmaceuticals which are bioequivalent to innovative pharmaceutical is also related to the political and legal environment of their market. If we look at pharmaceutical industry globally we can see that regulations toward generic pharmaceutical are different in different countries. For example, in United States they have the Hatch-Waxman ACT 1984including Abbreviated New Drug Application which reduce the drugs approval period and give the chance to Generic companies to have a 180 day exclusivity period if the generic company can submit an abbreviated new drug application before other generic competitors. In Europe regulations are different in each country for example, United Kingdom and the Netherlands are very similar to USA, and countries such as Germany and France are more physician-driven or branded generics market and the cost of sale for generic products are higher in these countries. Market for generic drugs in the rest of...
Words: 1493 - Pages: 6
...Case Study TEVA Strengthens Security for Software Assets with MKS Integrity “One of the main measures for success in the implementation of the MKS Integrity Suite was the reduction in the amount of paper and forms that get manually pushed from person to person. By simply automating service request forms and routing them via electronic workflows we have become much more effective, and dramatically reduced our time spent managing projects.” Tom Loane, Chief Information Officer , TEVA Pharmaceuticals Company Overview TEVA USA is a wholly-owned subsidiary of TEVA Pharmaceutical Industries Ltd., Israel’s largest pharmaceutical manufacturer operating globally in 30 countries on 5 continents. TEVA is among the top 20 pharmaceutical companies and the largest generic pharmaceutical companies in the world. The company has approximately 14,000 employees worldwide with production facilities in Israel, North America, Europe and Mexico. TEVA USA has an aggressive Research & Development effort and one of the best overall ANDA approval records in the industry. The company’s mission is to play a leading role in the transformation of the U.S. healthcare system through its preeminence in the development, manufacturing and marketing of pharmaceuticals. The Challenge As a pharmaceutical company operating in the U.S., TEVA must comply with Food and Drug Administration (FDA) regulations. The FDA requires stringent application development and change control practices surrounding software...
Words: 1059 - Pages: 5
...Teva Strategy Overview February 21, 2008 Forward-Looking Statements TODAY S PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS, WHICH EXPRESS THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT. SUCH STATEMENTS INVOLVE A NUMBER OF KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES THAT COULD CAUSE TEVA'S FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS TO DIFFER SIGNIFICANTLY FROM THE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARDLOOKING STATEMENTS. IMPORTANT FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE RISKS RELATING TO: TEVA'S ABILITY TO ACCURATELY PREDICT FUTURE MARKET CONDITIONS, TEVA'S ABILITY TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE ADDITIONAL PHARMACEUTICAL PRODUCTS, THE INTRODUCTION OF COMPETING GENERIC EQUIVALENTS, THE EXTENT TO WHICH TEVA MAY OBTAIN U.S. MARKET EXCLUSIVITY FOR CERTAIN OF ITS NEW GENERIC PRODUCTS AND REGULATORY CHANGES THAT MAY PREVENT TEVA FROM UTILIZING EXCLUSIVITY PERIODS, COMPETITION FROM BRAND-NAME COMPANIES THAT ARE UNDER INCREASED PRESSURE TO COUNTER GENERIC PRODUCTS, OR COMPETITORS THAT SEEK TO DELAY THE INTRODUCTION OF GENERIC PRODUCTS, POTENTIAL LIABILITY FOR SALES OF GENERIC PRODUCTS PRIOR TO A FINAL RESOLUTION OF OUTSTANDING PATENT LITIGATION, INCLUDING THAT RELATING TO THE GENERIC VERSIONS OF ALLEGRA , NEURONTIN , LOTREL , FAMVIR , AND PROTONIX , THE IMPACT OF CONSOLIDATION OF OUR DISTRIBUTORS AND CUSTOMERS, THE EFFECTS OF COMPETITION ON OUR INNOVATIVE PRODUCTS, ESPECIALLY COPAXONE SALES, THE IMPACT...
Words: 7679 - Pages: 31
...PRESCRIPTION SAVINGS CARD First NUVIGIL Prescription FREE* Refills as low as $5* FOR PHARMACISTS First Prescription is FREE* On the first fill, your patient will receive up to 30 NUVIGIL tablets at no cost, subject to terms and limitations. FOR PATIENTS Refills as low as $5* On all future NUVIGIL fills, your patient’s out-of-pocket expense will be as low as $5 for each prescription refill with a maximum savings of up to $50 per prescription. INSURED PATIENT BILLING Submit a primary claim to your patient’s insurance, and then submit a secondary coordination of benefits (COB) claim to AlphaScrip. BIN: 610600 PCN: AS Group and ID numbers: located on the card PRIOR AUTHORIZATION If your insured patient’s insurance provider denied the primary claim due to a Prior Authorization (PA) requirement, please initiate the PA process to help your patient save on future NUVIGIL prescriptions If you have questions regarding prior authorization or need forms to assist your patient initiate the prior authorization process, please go to CoverMyMeds.com for assistance PATIENTS WITHOUT INSURANCE COVERAGE FOR NUVIGIL Submit a primary claim to AlphaScrip using Other Coverage Code: 00 or 01 BIN: 610600 PCN: AS Group and ID numbers: located on the card For assistance or questions regarding pharmacy billing, please contact the AlphaScrip Pharmacy Help Desk at 1-877-274-3244. The correct Other Coverage Code is required (see below). Editing the Other Coverage Code may be necessary. 03:...
Words: 935 - Pages: 4
...Running Head: Decisions in Paradise Part II Decisions in Paradise Part II NAME MGT 350 January 23, 2012 Introduction Within the context of Decisions in Paradise I, I discussed some of the different obstacles that TEVA, USA is encountering while trying to enter the country of Kava, a South Pacific Island. I also shared different approaches that my company TEVA, USA can take to address the many challenges that the island presents. Any solution that I, or my partners, propose will have an effect on Kava and this should be taken into consideration when implementing our techniques. The process of assessing the available solutions will be explored within Decisions in Paradise II. The most difficult problem to overcome is that Kava is a hard island to inhabit because of the unavoidable issues the face with disasters and disease. In addition to the mess that the island is in, the office that TEVA occupies is also in havoc. They lack sufficient employees and the office in unorganized. After identifying the problems at hand, I have determined that the basic solutions would be; hire a new receptionist, clean up the office space, and implementing contingency plans for every natural disaster that may impact the land. This would include a safety plan, a cleaning plan, and a safe place for everyone to go when disasters do strike. Decision-making Technique Several influences have been identified to lead to the issues that are affecting Kava today. The main...
Words: 887 - Pages: 4
...the island to analyze the possibility of the plans of the Teva Pharmaceuticals to increase its presence in the island. Determining Factors Affecting the Decision Implementation The disaster threats relative to the geographic location of Kava pose considerable risks to any business operating in the island. Teva Pharmaceuticals will not be exempted from that. The threats also pose real danger to the health of the people of Kava. The risks from the disaster threats could significantly affect the health of the population particularly if accessibility to affordable health and medical supplies is difficult. The threats from AIDS/HIV alone could be devastating but the threat could be eased with available protective device such as affordable and easy accessible condom sheaths. The situation in Kava could be a great opportunity for the Teva Pharmaceuticals to expand its mission which is “to play a leading role in the transformation of the U.S. healthcare system through its pre-eminence in the development, manufacture and marketing of generic pharmaceuticals (TEVA USA., 2010, para 2)”. The company can expand that mission to the healthcare system of Kava Island highly vulnerable to many threats particularly storm, tsunami, earthquake, flood, fire, petroleum spills, AIDS/HIV, and avian flu (University of Phoenix, 2010). The condition of Kava may not be highly favorable but the island also has some benefits to offer to Teva...
Words: 1991 - Pages: 8
...makers to test products that may be helpful to children. During exclusivity periods, competing generic copies are generally prohibited from entering the market. The FDA granted the six-month pediatric extension for sildenafil on Feb. 9, according to the FDA website. The patent extension applies to any drug containing sildenafil, even Viagra, which is only approved for use by men with erectile dysfunction and not for use by children. As a result, the U.S. period of exclusivity for Viagra would extend by six months until April 2020, said Pfizer spokeswoman Victoria Davis. That is based on a patent due to expire in 2019, which covers sildenafil's use to treat ED. This patent was upheld by a federal judge last year, though Teva Pharmaceutical Industries Ltd. (TEVA), which challenged the patent's validity, has appealed that decision. The basic patent for sildenafil was due to expire in March 2012. The pediatric exclusivity period now extends to...
Words: 254 - Pages: 2
...INTRODUCTION TO THE THIRD EDITION Since the second edition of this book published in 2007, the globalization of the economy has seen its momentum challenged by two financial crises. Starting in the USA, the so-called ‘subprime’ crisis has obliged governments around the world to engage in Neo-Keynesian policies in order to consolidate the stumbling global financial system. More recently the ‘Eurozone’ crisis has called into question one of the most ambitious international cooperations and has seen populations asking for more protectionism. In the Middle East, dictatorial regimes have been ousted by the revolutionary ‘Arab Spring’ and the newly formed governments are trying to find a way between global exchange and Islamic tradition. During these difficult times, emerging countries from Asia, Latin America and Africa have increasingly asserted their newly found economic and financial power and demanded a bigger participation in world governance. The tsunami that struck Fukushima in Japan in March 2011 creating a nuclear accident has convinced many nations to reconsider their energy policy. Despite all of this, globalization, even though criticized, is still active. Firms are moving to the new emerging economies in order to capture the consumption appetite of the growing middle classes. It is still relevant and important to put together all aspects of global strategic management. This third edition is still about global firms and global management. Its objective remains to help...
Words: 2794 - Pages: 12
...A “Calibrated Approach”: Pharmaceutical FDI and the Evolution of Indian Patent Law Web version: August 2007 Authors: Katherine Connor Linton and Nicholas Corrado1 Abstract India has charted its own intellectual property (IP) path over the last 35 years, attempting to foster the growth of a domestic pharmaceutical industry and access to medicine while, more recently, also addressing the requirements of the international IP regime. Multinational companies (MNCs) have responded to India’s movement towards compliance with the W TO intellectual property agreement, TRIPS, by increasing the quantity and quality of foreign direct investment (FDI) in the areas of pharmaceutical research and development (R&D) and manufacturing. By contrast, MNCs have adopted a more cautious attitude toward the patenting and commercialization of new pharmaceutical products in India, waiting to see how Indian courts and patent offices interpret the new laws, and awaiting the enactment of longdebated data protection legislation. The ultimate success of the Indian “calibrated approach” to fostering the domestic industry and access to medicine while also addressing international IP requirements remains to be seen. 1 Katherine Connor Linton (katherine.linton@usitc.gov) is the International Trade Analyst for Intellectual Property and Nicholas Corrado was a law student intern in the Office of Industries of the U.S. International Trade Commission (USITC). The views expressed are those of Ms. Linton and...
Words: 6873 - Pages: 28
...Journal of Business & Industrial Marketing Emerald Article: Activity-based costing: a powerful tool for pricing John C. Lere Article information: To cite this document: John C. Lere, (2000),"Activity-based costing: a powerful tool for pricing", Journal of Business & Industrial Marketing, Vol. 15 Iss: 1 pp. 23 - 33 Permanent link to this document: http://dx.doi.org/10.1108/08858620010311539 Downloaded on: 05-04-2012 References: This document contains references to 4 other documents To copy this document: permissions@emeraldinsight.com This document has been downloaded 4868 times. Access to this document was granted through an Emerald subscription provided by CAIRO UNIVERSITY For Authors: If you would like to write for this, or any other Emerald publication, then please use our Emerald for Authors service. Information about how to choose which publication to write for and submission guidelines are available for all. Additional help for authors is available for Emerald subscribers. Please visit www.emeraldinsight.com/authors for more information. About Emerald www.emeraldinsight.com With over forty years' experience, Emerald Group Publishing is a leading independent publisher of global research with impact in business, society, public policy and education. In total, Emerald publishes over 275 journals and more than 130 book series, as well as an extensive range of online products and services. Emerald is both COUNTER 3 and TRANSFER compliant. The organization...
Words: 2360 - Pages: 10
...DECEMBER 21, 2012 CORPORATES RATING METHODOLOGY Global Pharmaceutical Industry Summary This rating methodology explains Moody’s approach to assessing credit risk for companies in the pharmaceutical industry globally. This document is intended to provide general guidance that helps companies, investors, and other interested market participants understand how key qualitative and quantitative risk characteristics are likely to affect rating outcomes for companies in the pharmaceutical industry. This document does not include an exhaustive treatment of all factors that are reflected in Moody’s ratings but should enable the reader to understand the qualitative considerations and financial information and ratios that are usually most important for ratings in this sector. This rating methodology replaces 1 the Global Pharmaceutical Industry Methodology published in October 2009. While reflecting many of the same core principles as the 2009 document, this update provides a more transparent presentation of the rating considerations that are usually most important for companies in this sector and incorporates refinements in our analysis that better reflect key credit fundamentals of the industry. No rating changes will result from publication of this rating methodology. This report includes a detailed rating grid and illustrative mapping examples that compare historical performance on factors in the grid to ratings of companies covered by this methodology. The purpose of the...
Words: 13613 - Pages: 55
...Strategy Formulation & Implementation Ranbaxy Laboratories Ltd 1. Summary: Indian pharmaceutical industry is estimated at $8 billion in 2013 and had been growing at an average rate of 8–9 %. The industry was highly fragmented with more than 1000 players out of which 30% of market was controlled by top ten companies and the rest of 70% by small companies. The Global pharmaceutical industry was estimated at $ 600 billion in 2013. Indian pharmaceutical industry has become more innovative and enterprising with more investment in R&D especially since the WTO agreement was signed. Indian drug makers command 10 per cent share in the USD 30 billion US generic drug market and also has the highest (over 150) US Foods & Drug Administration (FDA) approved facilities. US accounts for one-fourth of the Indian drug exports. The share of Indian pharma companies in the total approvals for generic drugs called Abbreviated New Drug Application (ANDA) has risen steadily. From 32 per cent in 2009, it went up to 38.5 per cent in 2013. Increasing share of Indian companies in total ANDAs approved by the USFDA can be attributed to increase spending by them for research and development (R&D) activities. As per CMIE’s database, the industry’s R&D expenses to sales ratio jumped to around five per cent in 2012-13 from around three per cent in 2003-04. The export of drugs from India is expected to grow by 4.2 per cent to USD 15.2 billion in 2013-14. Around USD 16.3 billion of drugs are likely to be...
Words: 11886 - Pages: 48
...Jona Gjylameti Finance 332 Procter & Gamble Procter and Gamble is the kind of company that is well known not only in the US market but in the international market as well. It is important to mention the fact that they are competing in 5 different segments while back on the year 2012 they decided to discontinue their snack business and to sell their products to the Kellogg Company. While I’d like to point out that in those 5 segments that they are competing, they are not the market leader for all of them. Based on the calculations, Procter and Gamble appears to have done well for the year of 2013, but if we stop and analyze how they did for the last 5 years we see that like any other company the ratios change indirectly. Their performance especially in terms of revenue growth, EBIT growth and earnings growth has been increasing over the years and this demonstrates the firm’s determination in being successful even though in 2012 they didn’t do as good as expected. P&G as mentioned above not only operates in the US market but also internationally, in other words they decided to expand even in the BRIC countries in order to achieve higher growth and revenue. If we analyze all of the calculations based on their yearly performance, I would say that as other companies might have reflected the 2008 crisis in their 10K reports, that wasn’t as critical as the 2012 ratios that we see for P&G. Moreover as I read a few articles and as they stated in their 10K, the fact that...
Words: 835 - Pages: 4
...Venture Capital Funding Proposal Venture Capital Funding Proposal 08 Fall 08 Fall EXECUTIVE SUMMARY Mobileye N.V. is a growing competitor in the Advanced Driver Assistance Systems (ADAS) industry. Mobileye is the successful developer of the EyeQ software on a low cost, automotive standards chip that allows for real time interpretation of data on visual surroundings, assisting drivers in prevention of collisions and identification of threats. The single camera system and strong relationship that Mobileye maintains with currently 18 original equipment manufacturers (OEMs) means the product is low cost, but still maintains quality and effectiveness. Mobileye being the developer of its flagship product, the EyeQ, with primary costs to production being the purchase of microchips on which the software is reproduced, means that cost of revenues is low, output is highly scalable and so Mobileye is capable of devoting substantial portions of future earnings to further research, improving existing products and gaining further growth through introduction of other ADAS products. This suggests extremely positive growth potential for Mobileye over the medium term. The ADAS market in which Mobileye operates shows a potential compound annual growth rate of more than 50% until 2018 (vli Ltd, 2014). This expected growth is attributed to several strong factors. Firstly, rapid technological progress has substantially lowered costs to production, meaning a much broader market of vehicles...
Words: 6152 - Pages: 25
